Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 4.35
PTN's Cash to Debt is ranked higher than
71% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. PTN: 4.35 )
PTN' s 10-Year Cash to Debt Range
Min: 1.4   Max: No Debt
Current: 4.35

Equity to Asset 0.69
PTN's Equity to Asset is ranked higher than
78% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. PTN: 0.69 )
PTN' s 10-Year Equity to Asset Range
Min: 0.04   Max: 0.95
Current: 0.69

0.04
0.95
F-Score: 3
Z-Score: -5.29
M-Score: 1647.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -34.50
PTN's Operating margin (%) is ranked higher than
62% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.79 vs. PTN: -34.50 )
PTN' s 10-Year Operating margin (%) Range
Min: -155850   Max: -21.25
Current: -34.5

-155850
-21.25
Net-margin (%) -17.46
PTN's Net-margin (%) is ranked higher than
64% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.93 vs. PTN: -17.46 )
PTN' s 10-Year Net-margin (%) Range
Min: -208620   Max: -12.64
Current: -17.46

-208620
-12.64
ROE (%) -13.70
PTN's ROE (%) is ranked higher than
66% of the 273 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. PTN: -13.70 )
PTN' s 10-Year ROE (%) Range
Min: -648.65   Max: -28.39
Current: -13.7

-648.65
-28.39
ROA (%) -9.85
PTN's ROA (%) is ranked higher than
66% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. PTN: -9.85 )
PTN' s 10-Year ROA (%) Range
Min: -214.29   Max: -14.01
Current: -9.85

-214.29
-14.01
ROC (Joel Greenblatt) (%) -2527.15
PTN's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.09 vs. PTN: -2527.15 )
PTN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7394.85   Max: -99.82
Current: -2527.15

-7394.85
-99.82
Revenue Growth (3Y)(%) -100.00
PTN's Revenue Growth (3Y)(%) is ranked lower than
51% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. PTN: -100.00 )
PTN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 155.4
Current: -100

-100
155.4
EBITDA Growth (3Y)(%) -37.40
PTN's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. PTN: -37.40 )
PTN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -65.2   Max: 15.3
Current: -37.4

-65.2
15.3
EPS Growth (3Y)(%) -41.20
PTN's EPS Growth (3Y)(%) is ranked higher than
56% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. PTN: -41.20 )
PTN' s 10-Year EPS Growth (3Y)(%) Range
Min: -63.3   Max: 5.3
Current: -41.2

-63.3
5.3
» PTN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

PTN Guru Trades in Q1 2014

Chuck Royce 35,000 sh (unchged)
» More
Q2 2014

PTN Guru Trades in Q2 2014

Chuck Royce 35,000 sh (unchged)
» More
Q3 2014

PTN Guru Trades in Q3 2014

Chuck Royce 35,000 sh (unchged)
» More
Q4 2014

PTN Guru Trades in Q4 2014

Chuck Royce 35,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PTN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.30
PTN's P/B is ranked higher than
94% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. PTN: 1.30 )
PTN' s 10-Year P/B Range
Min: 0.81   Max: 205
Current: 1.3

0.81
205
P/S 8.40
PTN's P/S is ranked lower than
55% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.52 vs. PTN: 8.40 )
PTN' s 10-Year P/S Range
Min: 0.84   Max: 81.13
Current: 8.4

0.84
81.13
EV-to-EBIT -1.84
PTN's EV-to-EBIT is ranked lower than
56% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PTN: -1.84 )
PTN' s 10-Year EV-to-EBIT Range
Min: -18.7   Max: 21.6
Current: -1.84

-18.7
21.6
Current Ratio 9.22
PTN's Current Ratio is ranked higher than
95% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. PTN: 9.22 )
PTN' s 10-Year Current Ratio Range
Min: 1   Max: 21.07
Current: 9.22

1
21.07
Quick Ratio 9.22
PTN's Quick Ratio is ranked higher than
96% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. PTN: 9.22 )
PTN' s 10-Year Quick Ratio Range
Min: 1   Max: 21.07
Current: 9.22

1
21.07
Days Sales Outstanding 85.54
PTN's Days Sales Outstanding is ranked higher than
71% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 78.80 vs. PTN: 85.54 )
PTN' s 10-Year Days Sales Outstanding Range
Min: 0.08   Max: 138.11
Current: 85.54

0.08
138.11

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.48
PTN's Price/Net Cash is ranked higher than
99% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PTN: 1.48 )
PTN' s 10-Year Price/Net Cash Range
Min: 0.76   Max: 271.11
Current: 1.48

0.76
271.11
Price/Net Current Asset Value 1.27
PTN's Price/Net Current Asset Value is ranked higher than
99% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PTN: 1.27 )
PTN' s 10-Year Price/Net Current Asset Value Range
Min: 0.75   Max: 109.38
Current: 1.27

0.75
109.38
Price/Tangible Book 1.25
PTN's Price/Tangible Book is ranked higher than
95% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.60 vs. PTN: 1.25 )
PTN' s 10-Year Price/Tangible Book Range
Min: 0.74   Max: 193.57
Current: 1.25

0.74
193.57
Price/Median PS Value 1.22
PTN's Price/Median PS Value is ranked higher than
77% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. PTN: 1.22 )
PTN' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 28.07
Current: 1.22

0.17
28.07
Earnings Yield (Greenblatt) -53.80
PTN's Earnings Yield (Greenblatt) is ranked lower than
66% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. PTN: -53.80 )
PTN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.6   Max: 31027.6
Current: -53.8

4.6
31027.6

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 14 5 103 201
EPS($) -0.07 -0.18 0.43 0.41
EPS without NRI($) -0.07 -0.18 0.43 0.41

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:PTNA.Germany,
Palatin Technologies Inc was incorporated in Delaware in 1986. The Company is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, cachexia (wasting syndrome) and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of acute asthma, heart failure, hypertension and other cardiovascular diseases. The Company's main product in development is bremelanotide for the treatment of female sexual dysfunction. It also has drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, dermatologic diseases and inflammatory diseases. It has an exclusive global research collaboration and license agreement with AstraZeneca AB (AstraZeneca) to commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome. The Company's main competitors, includes pharmaceutical, biopharmaceutical and biotechnology companies.
» More Articles for PTN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Palatin Technologies to Present at the 27th Annual ROTH Conference Mar 09 2015
Palatin Launches reconnectstudy.com in Support of Bremelanotide Phase 3 Program for Female Sexual... Feb 20 2015
PALATIN TECHNOLOGIES INC Financials Feb 19 2015
Macrocure (MCUR) in Focus: Stock Falls 5.5% - Tale of the Tape Feb 17 2015
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2015 Results; Teleconference and... Feb 13 2015
PALATIN TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 13 2015
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2015 Results; Teleconference and... Feb 13 2015
Q2 2015 Palatin Technologies Inc Earnings Release - Before Market Open Feb 13 2015
PALATIN TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report Feb 12 2015
PALATIN TECHNOLOGIES TO PRESENT AT THE BIO CEO & INVESTOR CONFERENCE Feb 11 2015
Palatin Technologies, Inc. To Report Second Quarter Fiscal Year 2015 Results Teleconference and... Feb 09 2015
Palatin Technologies To Present At The BIO CEO & Investor Conference Feb 06 2015
PALATIN TECHNOLOGIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... Dec 30 2014
Horizon Technology Finance Leads $10 Million Venture Loan for Palatin Technologies Dec 29 2014
Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction Dec 29 2014
Palatin Completes $20 Million Equity and $10 Million Debt Financings Dec 24 2014
Palatin Completes $20 Million Equity and $10 Million Debt Financings Dec 24 2014
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and... Nov 18 2014
PALATIN TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 18 2014
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and... Nov 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK